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Background Maternal supplementation with omega-3
polyunsaturated fatty acids (n-3 PUFA) may modulate immune
responses and allergy in neonates and children.
Objective To determine if n-3 PUFA supplementation during
pregnancy and lactation reduces risk for childhood allergic disease.
Search strategy We searched Medline and all evidence-based
medicine reviews for randomised controlled trials comparing the
effects of n-3 PUFA and placebo supplementation during
pregnancy and/or lactation on childhood allergic diseases and
inflammatory cytokines.
Selection criteria We included studies reporting on food
allergy, response to the egg skin prick test (SPT), atopy and
asthma in infancy and childhood as well as production of
interleukin-13 and interferon-gamma (IFN-c), two cytokines
involved in the pathogenesis of asthma. For assessment of
inclusion, two authors reviewed all abstracts for suitability and
independently extracted data.
Data collection and analysis Two-by-two tables were constructed
and odds ratios (OR) were calculated for the outcomes: response
to the SPT, food allergy, atopy and asthma in childhood. The
assays differed so data on inflammatory markers were reported in
narrative form.
Main results Five randomised controlled trials (n = 949) were
included. n-3 PUFA supplementation during pregnancy reduced
12-month prevalence of positive egg SPT (two trials, 12/87 versus
32/100, OR 0.33, 95% CI 0.16, 0.70) and childhood asthma (two
trials, 10/303 versus 17/179, OR 0.349, 95% CI 0.154, 0.788) and
significantly reduced cord blood interleukin-13 levels.
Supplementation during lactation did not prevent asthma, food
allergy or atopy.
Conclusion n-3 PUFA supplementation during pregnancy
decreases childhood asthma and response to SPT.
Keywords Allergy, meta-analysis, omega-3 polyunsaturated fatty
acids, perinatal supplementation.
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Introduction
The incidence of allergic diseases in the industrialised world
has increased significantly over the past 20–40 years.1 One
possible explanation for the observed increase involves the
concurrent change in Western diet from a relative balance
between anti-inflammatory omega-3 fatty acids (n-3 PUFA)
and proinflammatory omega-6 fatty acids (n-6 PUFA), to a
diet in which n-6 PUFA are overwhelmingly predominant.1
Allergic diseases are typically diagnosed in early infancy,
further suggesting that causative events take place in utero
or during the neonatal period.2 Investigators have specu-
lated that the predisposition to allergic disease may result
from insufficiently balanced T helper cell type 1 and 2
(Th1 and Th2) pathways during fetal life.3
It has been proposed that high concentrations of dietary
n-6 PUFA favour a Th2 differentiation of the immune sys-
tem during ontogeny and development.1 One mechanism
whereby n-3 PUFA may alter the T helper cell balance is
through suppression of interleukin-13 (IL-13) production.
Interleukin-13 may be related to allergic diseases through
its role in inducing immunoglobulin E (IgE) synthesis in
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B cells and Th2 type differentiation in T cells.4 Likewise,
aberrant or reduced expression of the cytokine, interferon-
gamma (IFN-c) has also been associated with a number of
autoinflammatory and autoimmune diseases.5,6
It is now known that immunological abnormalities pre-
cede the development of allergic disease.2 Additionally, the
immature immune system is highly susceptible to immuno-
modulatory environmental conditions, particularly in the
prenatal and postnatal periods.1 It has been hypothesised
that maternal diet may impact neonatal immune develop-
ment and subsequently alter allergic responses of neonates.
Specifically, maternal intake of n-3 PUFA has been impli-
cated; animal and human studies support the hypothesis
that n-3 PUFA suppress cell-mediated immune responses.7
Docosahexaenoic acid (DHA) and eicosapentaenoic acid
(EPA) are two biologically active n-3 PUFA with major
immunomodulatory functions. High intake of n-3 PUFA
decreases the proportion of arachidonic acid (AA) in
immune cell membranes and subsequently decreases cell
responsiveness to exogenous stimuli. The DHA and EPA
competitively inhibit the metabolism of AA, resulting in
reduced production of the ‘pro-allergic’ four-series leuko-
trienes and the two-series prostaglandins. n-3 PUFA are
also known to inhibit the activation of proinflammatory
cell signals.1
The known biological activities of n-3 PUFA have led
investigators to hypothesise that supplementation during
pregnancy and lactation may serve as a method of primary
prevention of allergic diseases in childhood. This systematic
review synthesises the results of several randomised con-
trolled trials that have investigated the effects of maternal
supplementation with n-3 PUFA during pregnancy and/or
lactation for primary prevention of food allergy, atopy




We identified relevant studies by a computer search of
MEDLINE and MEDLINE In-Process databases for the
years 1950 to October 2010. We included In-Process and
Other Non-Indexed Citations available in MEDLINE up to
21 October 2010. We also searched all EBM reviews, which
included Cochrane Database of Systematic Reviews, ACP
Journal Club, DARE, CCTR, CMR, HTA and NHSEED.
The searches were conducted using combinations of the
following medical subject heading terms: ‘polyunsaturated
fatty acids’, ‘n-3 PUFA’, ‘omega 3 fatty acids’, ‘DHA’,
‘EPA’, ‘fish oil’, ‘pregnancy’, ‘lactation’, ‘allergy’, ‘atopy’,
‘dermatitis’, ‘asthma’, ‘wheezing’ and ‘skin prick’. We did
not apply a language restriction. We supplemented our
search by cross-checking the reference lists of all relevant
review articles and by searching by principal investigators’
names for secondary analyses of all identified randomised
controlled trials. We contacted primary authors for clarifi-
cation of data when necessary.
Study selection
We included studies comparing supplementation in preg-
nancy and lactation with n-3 PUFA or placebo for primary
prevention of allergic disease in neonates, infants and
children.
Types of studies
All included studies were randomised controlled trials.
Types of participants
All included participants were pregnant or lactating women
and their offspring. Two of the included studies required a
personal or family history of allergic disease for enrol-
ment,8,9 whereas three studies did not require any history
of risk factors for allergic disease.10–12
Types of interventions
All included studies involved supplementation of pregnant
or lactating women with n-3 PUFA or placebo.
Types of outcome measures
To be included in this systematic review, the studies had to
report on one of the following clinical or immunological
outcomes in neonates, infants or children: asthma, atopy
and food allergy as a clinical diagnosis or as response to
the egg skin prick test (SPT) at any time during the first
12 months of life. We included only studies in which diag-
noses were verified by medical or nursing clinicians.
We also included studies reporting on production of two
inflammatory cytokines involved in the allergic response:
IL-13 and IFN-c.
Validity assessment
Two reviewers (CK and EM) initially screened the title,
abstract and keywords of all 81 articles identified by the
searches. The majority of these were excluded because they
were not randomised controlled trials. These reviewers then
selected 28 potentially relevant articles8–35 that corre-
sponded to eight randomised controlled trials and their
secondary analyses. Full texts were then independently
viewed for further consideration for inclusion. One rando-
mised controlled trial that was available in abstract form
was excluded because only interim analysis data were avail-
able.33 We excluded one additional randomised controlled
trial because n-3 PUFA supplementation was initiated after
pregnancy and lactation were completed.13–18 Finally, we
excluded a third randomised controlled trial because the
intervention under study, blackcurrant oil, contained a
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mixture of n-6 and n-3 PUFA.35 Two reviewers (CK and
EM) then independently applied specific inclusion criteria
to each of the potentially relevant articles and selected five
randomised controlled trials for inclusion.8–12 All primary
and secondary articles resulting from these trials were care-
fully reviewed for data on outcomes of interest. Additional
data from a published secondary analysis of one of the tri-
als were also included.19 All included studies are listed in
Table 1 and the flow of studies through the selection pro-
cess is shown in Figure 1.
Data abstraction and quality assessment
Included articles were duplicated for independent review by
two investigators (CK and EM) and data from each out-
come were independently extracted into two-by-two tables
in ‘events/totals’ form for supplemented and control
groups. Discrepancies were resolved by repeat manuscript
review and discussion until consensus was reached. In one
instance, an original author, Dr Lauritzen, was contacted
for clarification of data. For the cytokines of interest, mean
levels with 95% confidence intervals and significance levels
were extracted. Both reviewers independently assigned a
quality score to each included article based on the Scottish
Intercollegiate Guidelines Network scoring system for
randomised controlled trials.36 Individual elements that
contributed to the quality score included a clearly focused
research question, randomisation, allocation concealment,
blinding, analysis of drop-outs and follow up, standardised
measurement of outcomes, intention-to-treat analysis, and
similar baseline characteristics in the treatment and control
groups.
Study characteristics
Five randomised controlled trials with 949 participants
were included in this systematic review. All the included
studies were of high methodological quality. Four of the
included studies initiated n-3 PUFA supplementation dur-
ing pregnancy8,9,11,12,19 whereas one study began the sup-
plementation during lactation.10 Four of the included
studies reported on clinical outcomes8–10,12 and one
reported on inflammatory cytokines only.11 The included
studies are summarised in Table 1.
Quantitative data synthesis
Summary odds ratios (OR) were calculated using the fixed
effects method and confirmed using the random effects
method. By convention, an odds ratio of less than 1 indi-
cated that the event was more likely in the control group.
Between-study heterogeneity was assessed using Cochran’s
chi-square test (Q) and confirmed using the I-squared test
because of the small number of studies included for some
outcome comparisons.37 Heterogeneity was considered sig-
nificant at an alpha level of <0.05. We conducted prespeci-
fied subgroup analyses according to time of initiation of
n-3 supplementation (i.e. during pregnancy or lactation).
There were not enough extant studies to conduct subgroup
Table 1. Characteristics of included studies
Dunstan8,19 Lauritzen10 Krauss-Etschmann11 Olsen12 Furuhjelm9
Year 2003 2005 2008 2008 2009
Quality High High High High High
Follow up 83/98 (85%) 72/147 (49%) 141/157 (90%) 399/402 (99%) 117/145 (81%)
Intervention Fish oil; 3.7 g/day
n-3 PUFA
Fish oil; 1.5 g/day
n-3 LCPUFA
Fish oil; 0.5 g/day
DHA + 0.15 g/day
EPA
 2.7 g/day marine
n-3 PUFA + 2 mg
tocopherol/ml
1.6 g/day EPA +
1.1 g/day DHA +
23 mg a-tocopherol
Control Olive oil Olive oil Placebo not described Olive oil Soy oil; 2.5 g/day x-6
PUFA LA +
0.28 g/day x-3
PUFA LNA + 36 mg
a-tocopherol
Total no. 98 147 157 402 145
Duration of
intervention
From week 20 of
gestation until
delivery
First 4 months of
lactation
From week 22 of
gestation until
delivery
From week 30 of
gestation until
delivery






12 months 30 months Delivery 16 years 12 months
Outcomes Asthma, food allergy,
atopic dermatitis, skin
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analyses according to risk status of participants.
We assessed the studies for publication bias by constructing
funnel plots and assessing for asymmetry as described by
Egger et al.38 Egger’s regression intercept test was used to
quantify the bias captured by the funnel plot. Evidence of
asymmetry was specified at a significance level of P < 0.1.
We carried out all statistical analyses and generated all
Forrest plots using Comprehensive Meta-Analysis,
version 2.0, 2006, Englewood, NJ.
In the included studies, IL-13 and IFN-c production were
reported using different assays and units that precluded
statistical combination. Therefore we reported results for
these outcomes of interest in narrative form.
Results
Three of the included studies (n = 264) reported on clinical
diagnoses of food allergy in children.8–10 There was no sig-
nificant difference in food allergy between children of
mothers who received n-3 PUFA supplementation and chil-
dren of mothers receiving placebo (6/128 versus 16/136,
OR 0.462, 95% CI 0.155, 1.377; Figure 2). When only stud-
ies in which supplementation was started during preg-
nancy8,9 were considered, there were fewer children with
food allergies born to n-3 PUFA-supplemented mothers
than to placebo-supplemented mothers, but this difference
was not significant (4/92 versus 15/108, OR 0.341, 95% CI
0.101, 1.153). For the total analysis, there was no significant
between-study heterogeneity (Q = 2.975, df 2, P = 0.226,
I2 = 32.777) nor was there evidence of publication bias
(Egger’s regression intercept P = 0.998).
Two of the included studies (n = 187) reported on the
period prevalence of positive response to the egg SPT in
children up to 12 months old after maternal n-3 PUFA
supplementation during pregnancy.8,9 Supplementation sig-
nificantly reduced a positive SPT response to egg (12/87
versus 32/100, OR 0.332, 95% CI 0.158, 0.700; Figure 3).
There was no significant between-study heterogeneity
(Q = 0.003, df 1, P = 0.957, I2 = 0.000). There were too
few included studies to assess publication bias.
We included three studies (n = 262) that reported on
atopy (eczema or atopic dermatitis) in children after
maternal n-3 PUFA supplementation during pregnancy and
lactation.8–10 There was no difference in atopic dermatitis
between children born to mothers receiving n-3 PUFA or
placebo (27/128 versus 32/134, OR 0.924, 95% CI 0.488,
1.750; Figure 4). This result was not different when the one
study10 that commenced supplementation during lactation
was excluded. There was significant between-study hetero-
geneity for this comparison (Q = 6.731, df 2, P = 0.035,
I2 = 70.287), but there was no evidence of publication bias
53 abstracts excluded: 
22 observational studies  
29 review articles  
2 editorials 
8 relevant RCTs  
(26 full text articles, 2 
abstracts) 
reviewed 
3 RCTs (7 full text, 1 abstract) 
excluded: 
2 RCTs did not meet inclusion 
criteria 
1 RCT was an interim analysis 
5 RCTs included  
(19 full text, 1 
abstract)  
67 titles retrieved from search of 
Medline, Medline In Process and all 
EBM reviews 
3 titles added from reference list 
searches 
11 titles added from principal 
investigator searches 
81 titles and 
abstracts reviewed 
Data abstracted from 
6 full text articles 
with outcomes of 
interest 
14 articles did not 
contain data on 
outcomes of interest 
Figure 1. Summary of stages of study inclusion and exclusion for the
meta-analysis; RCT, randomised controlled trial.
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper
ratio limit limit Z-value p -value
Dunstan 2003 0.616 0.137 2.765 –0.632 0.527
Lauritzen 2005 1.588 0.137 18.461 0.370 0.712
Furuhjelm 2009 0.108 0.013 0.872 –2.088 0.037
0.462 0.155 1.377 –1.386 0.166
0.01 0.1 1 10 100
Favours n-3 Favours control
Summary
Figure 2. Odds ratio and 95% confidence intervals for food allergy outcomes.
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for this comparison (Egger’s regression intercept
P = 0.627).
Three of the included studies (n = 546) reported on the
outcome of asthma in children after supplementation dur-
ing pregnancy or lactation.8,10,12 In the analysis of all stud-
ies combined, there was no difference in asthma between
children in the n-3 PUFA-supplemented and placebo
groups (21/339 versus 23/207, OR 0.583, 95% CI 0.300,
1.133; Figure 5). However, in the analysis of the two stud-
ies in which supplementation was initiated during preg-
nancy,8,12 n-3 PUFA supplementation significantly reduced
asthma during childhood (10/303 versus 17/179, OR 0.349,
95% CI 0.154, 0.788). In the total analysis, there was no
significant between-study heterogeneity. (Q = 4.559, df 2,
P = 0.102, I2 = 56.126), nor was there evidence of publica-
tion bias (Egger’s regression intercept P = 0.98).
Two of the included studies reported decreased IL-13
production in the cord blood of infants born to women
receiving n-3 PUFA compared with women receiving pla-
cebo.11,19 These outcome values could not be statistically
combined because of the differing assays and units of
reporting. Dunstan et al.19 reported that maternal n-3
PUFA supplementation significantly reduced IL-13 levels as
measured by ELISA (P < 0.05). Krauss-Etschmann et al.11
measured mRNA for IL-13 and reported that IL-13 mRNA
levels were significantly reduced in the n-3 PUFA group
compared with placebo (P < 0.05).
The three included studies that reported on IFN-c levels
in neonates or infants reported differing effects of supple-
mentation on IFN-c.10,11,19 Dunstan et al.19 found no
difference in IFN-c response in cord blood; however, levels
of IFN-c were below detection in more than 95% of
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper
ratio limit limit Z-value p -value
Dunstan 2003 0.340 0.113 1.023 –1.919 0.055
Furuhjelm 2009 0.326 0.119 0.896 –2.172 0.030
0.332 0.158 0.700 –2.898 0.004
0.01 0.1 1 10 100
Favours n-3 Favours control
Summary
Figure 3. Odds ratio and 95% confidence intervals for skin prick outcomes.
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper
ratio limit limit Z-value p -value
Dunstan 2003 1.888 0.767 4.648 1.383 0.167
Lauritzen 2005 0.968 0.234 3.998 –0.045 0.964
Furuhjelm 2009 0.267 0.082 0.862 –2.208 0.027
0.924 0.488 1.750 –0.242 0.809
0.01 0.1 1 10 100
Favors n-3 Favors control
Summary
Figure 4. Odds ratio and 95% confidence intervals for atopy outcomes.
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-value p -value
Dunstan 2003 0.325 0.062 1.712 –1.326 0.185
Lauritzen 2005 1.613 0.512 5.085 0.817 0.414
Olsen 2008 0.357 0.140 0.909 –2.161 0.031
0.583 0.300 1.133 –1.593 0.111
0.01 0.1 1 10 100
Favors n-3 Favors control
Summary
Figure 5. Odds ratio and 95% confidence intervals for asthma outcomes.
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samples. Lauritzen et al.10 reported that lipopolysaccharide
induced IFN-c was significantly greater in the n-3 PUFA-
supplemented group compared with the controls at
2.5 years of age. By contrast, Krauss-Etschmann11 found no
difference in IFN-c in cord blood.
Comment
We conducted a systematic review of recent studies to iden-
tify the role that perinatal n-3 PUFA supplementation plays
in infant and childhood allergy, asthma, atopy and inflam-
matory markers. We found that maternal n-3 PUFA supple-
mentation during pregnancy significantly reduced the
prevalence of positive egg SPT in infants up to 12 months
old as well as the prevalence of childhood asthma, but had
no effect on childhood atopy (atopic dermatitis). In chil-
dren whose mothers received prenatal n-3 PUFA supple-
mentation, there was a non-significant trend towards
reduction in clinical food allergy. Based on the odds ratios
from the included studies, the reduction in food allergies
might be as high as 66%; however, given the small sample
and wide confidence intervals, further studies are needed to
test this hypothesis. Prenatal n-3 PUFA supplementation
significantly reduced fetal IL-13 production. In contrast pre-
natal supplementation did not alter IFN-c.
Included studies were assessed and rated by two inde-
pendent evaluators. The high methodological quality of
these included studies was a source of strength in this
meta-analysis. Four of the five included studies had follow-
up data for 80% of the children of supplemented mothers,
another index of high methodological quality.39 Data were
analysed both with and without the study that commenced
supplementation during lactation.10 In general, this study
showed less of a trend toward benefit for most of the stud-
ied clinical outcomes than the studies in which supplemen-
tation was initiated during pregnancy. However, inclusion
of this study did not alter the conclusions of the analysis,
except for the outcome of childhood asthma.
The administration of n-3 fatty acids was found to sig-
nificantly reduce childhood asthma in the analysis of stud-
ies in which supplementation was initiated during
pregnancy but not in the combined analysis. This result
was heavily influenced by the Olsen study, which used an
olive oil placebo.12 This leads to the question of whether
olive oil supplementation during pregnancy might increase
the risk for asthma, incorrectly suggesting a benefit for n-3
fatty acids. A recently published cohort study, however,
suggests that a diet rich in olive oil during pregnancy may
itself prevent childhood asthma,40 so it is more likely that
the placebo in the Olsen study may have tended to mask a
beneficial effect of the n-3 fatty acid supplementation.
Several potential limitations of our analysis need to be
noted. First, the trials included participants from Sweden,
Denmark, Hungary, Western Australia, Norway, Germany
and Spain. This may limit the generalisability of the results
or may, conversely, underestimate the magnitude of benefit
of supplementation by studying women who already have a
moderate baseline n-3 PUFA intake. Variation in the die-
tary habits between countries may result in considerable
differences in baseline fatty acid states and subsequent
responses to supplementation. For example, one included
study took place in Sweden9 where the n-3 PUFA to n-6
PUFA ratio is approximately 5:134 in contrast to many
other Western countries in which it is estimated to be
between 20:1 and 30:1.41 The women’s diets in any one
study may not necessarily represent those of other Western
populations.
Second, the different doses of supplementation in the
combined studies may also represent a weakness of this
meta-analysis, given that n-3 PUFA supplementation may
have an inverted U-shaped dose–response curve, with
moderate doses conferring more benefit than high doses in
some models.42 Likewise, the relatively small number of
extant studies and small sample sizes limited the precision
of our estimates.
Finally, although a positive SPT indicates the presence of
food-specific IgE antibodies,43 a positive response may be
seen in tolerant individuals and does not necessarily repre-
sent food allergy.44 Although we found a significant reduc-
tion in this intermediate outcome measure, future
randomised controlled trials of prenatal n-3 fatty acid sup-
plementation are needed to assess the effect on clinical
allergic disease as well as the durability of any beneficial
effects.
Our study differed from the previously published sys-
tematic review of n-3 and n-6 PUFA supplementation for
primary prevention of allergic disease45 in that we included
only studies of perinatal n-3 PUFA supplementation and
excluded studies of n-6 PUFA supplementation. Anandan
et al.45 included studies of fortification of infant formula
and diet in early childhood, and it is possible that this rela-
tively late initiation of supplementation accounts for the
lack of trend toward benefit in their analysis. That finding
is in accord with the results of the included Lauritzen et al.
trial10 that began n-3 PUFA supplementation during lacta-
tion, as well as the excluded Mihrshahi et al. trial,14 which
began infant n-3 supplementation after the conclusion of
pregnancy and lactation. In addition, our study included
the Furuhjelm study, which was published subsequent to
the search date of the Anandan et al. systematic review.9,45
More studies are needed before any clinical recommen-
dations can be made regarding the benefit of n-3 PUFA
supplementation in decreasing childhood allergy. This
would allow for appropriate comparisons among women
exposed to varying dietary patterns and examination of
the impact of supplementation duration and dosage.
The n-6 to n-3 PUFA ratio status of study participants
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needs to be taken into account when designing future stud-
ies. Decreasing n-6 PUFA in the diet while supplementing
with n-3 PUFA may prove to be maximally effective in sta-
bilising this ratio.
It is also important to consider the safety of supplemen-
tation, especially in pregnant populations. Fish oil does
have a potential antithrombotic effect, although available
clinical trial evidence does not demonstrate any increased
risk for bleeding at delivery after prenatal fish oil supple-
mentation.46,47 Fish oil supplementation may also prolong
gestational length by 2.6 days on average, which may be
considered beneficial or harmful, depending on circum-
stance.46 Other potential risks with fish oil supplementation
are fatty acid oxidation, hypervitaminosis and exposure to
environmental toxins; these risks can be minimised by
rigorous purification.48 In assessing the overall risk to
benefit trade-offs during pregnancy it should be noted that
in a recent large randomised controlled trial, compared
with placebo, prenatal n-3 PUFA supplementation reduced
serious fetal/neonatal adverse events, defined as death,
major congenital anomaly, hospital treatment, or admission
to a neonatal intensive care unit.47
Our analysis found differing effects on allergic diseases
when supplementation was started during pregnancy com-
pared with during lactation. Fetal immune responses to
antigens have been detected as early as the 22nd week of
gestation;6 the results of our analysis support the hypothe-
sis that supplementation in the postnatal period may be
too late to modify the allergic response. Future large rando-
mised controlled trials to explore the role of supplementa-
tion during pregnancy should begin in early gestation, at
least before 25 weeks. Such research should pay careful
attention to optimal dosages and allow for extended follow
up so that the effect on long-term allergic disease outcomes
can be determined. Preventative approaches are needed to
reduce the significant health burden of asthma and allergy,
which are among the most common chronic diseases
worldwide, affecting one in three children.49 If the role of
maternal n-3 PUFA supplementation on neonatal and
childhood allergy and atopy children is established, there
may be an opportunity for healthcare providers to recom-
mend maternal n-3 PUFA supplementation for the primary
prevention of allergic disease.
Conclusion
Our systematic review demonstrates that n-3 PUFA supple-
mentation during pregnancy decreases childhood asthma
and response to SPT, while supplementation begun during
lactation does not significantly alter these clinical outcomes.
Supplementation with n-3 PUFA also reduces IL-13 in cord
blood, indicating prenatal modulation of the immune
response that may lead to allergic diseases in childhood.
Large randomised trials are needed to confirm the preven-
tative effects of prenatal n-3 PUFA supplementation on
allergic diseases of childhood.
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Commentary on fetal programming: role of fish oil in pregnancy for
the prevention of asthma and allergies in the offspring
Two decades ago David Barker and colleagues published their first reports showing that an individual’s risk of devel-
oping ischaemic heart disease or metabolic syndrome in adult life is inversely related to his or her own birthweight
(Barker et al., Lancet 1989;2:577–80; Barker et al., BMJ 1991;303:1019–22). Around the same time, albeit a little later,
another group headed by Ekbom and Trichopoulos published their equally astonishing observations suggesting that
high birthweight is a risk factor for, and maternal pre-eclampsia a protective factor against, breast cancer (Ekbom
et al., Lancet 1992;340:1015–18). It was such epidemiological observations of relatively strong associations between
obstetric and perinatal variables on the one hand and of certain chronic diseases that develop many years later on the
other that—backed by complementary findings from animal experiments–laid the foundation for the theory that
became widely known as the fetal programming or intrauterine origins hypothesis. This postulates the existence of time
windows in the early periods of any individual’s life when there may be plasticity and susceptibility for insults or
influences that latently (i.e. without necessarily leaving any immediately apparent marks on the individual) may deter-
mine that person’s propensity for developing specific diseases many years later. The fetal programming hypothesis has
led to an immense interest in what is traditionally regarded as the field ‘belonging to’ obstetricians and neonatologists,
that is the maternal and fetal environment and its potential implications for the future health and development of the
child (Koletzko, Symonds and Olsen, Am J Clin Nutr 2011;73:671–2).
The programming concept has, over the years, been made broader and also more nuanced. Whereas the original
focus was on cardiometabolic diseases and cancer, a number of other diseases and health problems, ranging from
bone mineralisation and obesity to mental illnesses, are today also thought to be influenced—programmed—by factors
working in the earlier period of life. To indicate that programming may in principal take place during the whole per-
iod of development, including infancy and puberty, the broader term developmental programming is more commonly
used today; whereas the term early nutrition programming has been coined to designate developmental programming
caused specifically by nutritional factors. One of the most promising areas in the whole field is early nutrition pro-
gramming of atopic diseases.
On page 916 Mozurkewich and colleagues present their systematic review of randomised controlled trials that have
studied the impact of perinatal n-3 fatty acid supplementation on atopic diseases. They conclude that supplementa-
tion during pregnancy prevents asthma and reduces response to egg skin-prick test in the offspring; whereas their data
could not substantiate a corresponding effect of supplementation solely in the lactation period. The authors are fully
aware of the two main weaknesses of their analysis, which are the small total number of trials available and their het-
erogeneity in respect to design and study populations; and which, particularly in combination, create problems for
undertaking quantitative syntheses of results. For example, among the five trials included in the review, only one initi-
ated supplementation with n-3 fatty acids during the lactation period; and among the two studies that had examined
impact of supplementation during pregnancy on asthma, one had follow up until age 16 whereas the other followed
up for 12 months only. However, the paper is important because it gives an excellent overview of the available evi-
dence, which suggests that there is ‘something going on’ here of potentially great importance. Research is urgently
needed on which potential mechanisms could be underlying; Mozurkewich and colleagues mention several possibili-
ties, and more recently proposed anti-inflammatory mechanisms (Oh et al., Cell 2010;142:687–98) and epigenetic
mechanisms (Calder et al., Proc Nutr Soc 2010;69:373–80) should also be pursued. The empirical evidence for a possi-
ble effect needs to be consolidated (or refuted). Several excellent follow-up studies and trials are well underway and
Klemens et al.
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we should soon have firm evidence whether increased intake of long-chain n-3 fatty acids in pregnancy can prevent
asthma and allergies in the next generation.
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